Results 1 to 10 of about 72,405 (280)

Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis

open access: yesGMS Ophthalmology Cases, 2023
Objective: To present a case with infliximab-induced retrobulbar optic neuritis.Case description: A 58-year-old woman presented to our clinic with a two-day history of blurred vision in her right eye.
Dündar, Sema   +4 more
doaj   +2 more sources

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis

open access: yesCase Reports in Dermatology, 2017
A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled ...
Yuki Matsuura-Otsuki   +3 more
doaj   +2 more sources

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. [PDF]

open access: yesPLoS ONE, 2015
ObjectiveIn patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg).
Dario Sorrentino   +4 more
doaj   +2 more sources

Infliximab in the treatment of rheumatoid arthritis

open access: yesBiologics: Targets & Therapy, 2009
A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA).
A Perdriger
doaj   +2 more sources

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure

open access: yesGut and Liver
Background/Aims: Studies on elective switching to the subcutaneous (SC) formulation of infliximab revealed comparable efficacy and safety and higher infliximab level than those exhibited by intravenous (IV) infliximab.
June Hwa Bae   +10 more
doaj   +2 more sources

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

open access: yesClinical and Experimental Gastroenterology, 2009
Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s ...
Garrett Lawlor, Alan C Moss
doaj   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

open access: yesOpen Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A   +8 more
doaj   +1 more source

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

open access: yesGut and Liver, 2023
Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park   +9 more
doaj   +1 more source

Infliximab for Refractory Diffuse Sclerosing Osteomyelitis of the Mandible Associated With Ulcerative Colitis: A Case Report. [PDF]

open access: yesClin Case Rep
ABSTRACT Diffuse sclerosing osteomyelitis (DSO) of the mandible is a chronic nonbacterial inflammatory bone disease. We report a 65‐year‐old woman with ulcerative colitis who presented with swelling and pain of the left mandible. The lesion was refractory to tooth extraction, prolonged antibiotics, and nonsteroidal anti‐inflammatory drugs.
Yao M   +5 more
europepmc   +2 more sources

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study

open access: yesBMC Gastroenterology, 2022
Background Recent studies have confirmed that combined surgery and anti-TNF therapy could improve outcomes in patients with perianal fistulising Crohn’s disease (PFCD).
Ping Zhu   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy